SCHEMBL4412154

SCHEMBL4412154

COc1cc(OC)cc(N2CCN(CC(N)=O)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 1/20 0.50
GFER P55789 3/20 0.49
P4HB P07237 1/20 0.49
TSHR P16473 1/20 0.49
ADRB1 P08588 1/20 0.49
SCN9A Q15858 1/20 0.48
HTR1A P08908 2/20 0.48
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
RECQL P46063 1/20 0.47
DRD4 P21917 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4393525 0.88 MEN1 (0.64) GAAMEN1KMT2AGFERP4HB
SCHEMBL4395587 0.87 ALDH1A1 (0.63) LMNAMEN1KMT2AALDH1A1KDM4E
SCHEMBL3196635 0.84 KCNH2 (0.55) LMNAMEN1KMT2AHTR1AMAPT
Hydrochloric Acid SCHEMBL3194757 0.83 KCNH2 (0.53) LMNAMEN1KMT2AHTR1AMAPT
SCHEMBL4395782 0.82 MAPT (0.60) LMNAGAAALDH1A1GFERTSHR
SCHEMBL28201211 0.80 MEN1 (0.51) LMNAGAAMEN1KMT2AALDH1A1
SCHEMBL3436304 0.79 POLB (0.48) LMNAGAAMEN1KMT2AALDH1A1
SCHEMBL3434270 0.79 GAA (0.46) GAAMEN1KMT2AALDH1A1KDM4E
SCHEMBL3435121 0.79 USP8 (0.47) GAAMEN1KMT2AALDH1A1KDM4E
SCHEMBL3436540 0.79 HTR3E (0.55) LMNAGAAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 LMNA 2934/4885GAA 1611/4885MEN1 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.